Antiviral trial ties valacyclovir to faster cognitive decline

New York State Psychiatric Institute and Columbia University Medical Center investigators, with co-authors across additional US centers, report greater cognitive worsening at 78 weeks with valacyclovir than with placebo among adults with early symptomatic Alzheimer’s disease and herpes simplex virus (HSV) seropositivity.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup